Cerebrovascular events after herpes zoster infection: a risk that should be not underestimated

J Neurovirol. 2019 Aug;25(4):439-447. doi: 10.1007/s13365-019-00748-9. Epub 2019 May 8.

Abstract

The occurrence of a cerebrovascular event after a herpes zoster (HZ) infection represents a nightmare in clinical practice, especially in those patients with concomitant cardiovascular comorbidities/risk factors and disease related per se to a higher risk of zoster infection. Moreover, the absence of a consensus opinion regarding a specific and adequate prevention of cerebrovascular events in these patients further complicates the treatment. Accumulating evidences demonstrated that HZ and HZ ophtalmicus (HZO) increase the risk of cerebrovascular events in the short-and long-term periods. Moreover, patient's ages < 40 years old, despite having fewer traditional cardiovascular comorbidities, demonstrated a higher risk of cerebrovascular events after both HZ and HZO infection. Further prospective studies are needed to analyse the role of antiviral treatments and vaccination in these subjects to clarify if they could be able to reduce the risk of stroke after a zoster infection. In the meanwhile, physicians must be aware of a higher risk of cerebrovascular events, especially in younger patients, with few cardiovascular risk factors, after an HZ infection.

Keywords: Cerebrovascular events; Herpes zoster; Stroke.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Antiviral Agents / therapeutic use
  • Cerebrovascular Disorders / etiology*
  • Cerebrovascular Disorders / immunology
  • Cerebrovascular Disorders / prevention & control
  • Cerebrovascular Disorders / virology
  • Herpes Zoster / complications*
  • Herpes Zoster / immunology
  • Herpes Zoster / prevention & control
  • Herpes Zoster / virology
  • Herpes Zoster Vaccine / administration & dosage
  • Herpesvirus 3, Human / drug effects
  • Herpesvirus 3, Human / immunology
  • Herpesvirus 3, Human / pathogenicity*
  • Humans
  • Risk Factors
  • Vaccination

Substances

  • Antiviral Agents
  • Herpes Zoster Vaccine